Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Up 26.0% in April

Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) was the target of a significant growth in short interest in April. As of April 30th, there was short interest totalling 1,160,000 shares, a growth of 26.0% from the April 15th total of 921,000 shares. Currently, 4.6% of the company's stock are sold short. Based on an average daily trading volume, of 94,000 shares, the days-to-cover ratio is presently 12.3 days.

Vigil Neuroscience Price Performance

VIGL traded down $0.10 during midday trading on Friday, hitting $3.18. 79,302 shares of the company's stock traded hands, compared to its average volume of 86,224. The company has a market cap of $119.52 million, a PE ratio of -1.50 and a beta of 1.87. The stock's fifty day simple moving average is $3.07 and its 200-day simple moving average is $3.69. Vigil Neuroscience has a one year low of $2.50 and a one year high of $11.11.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last announced its quarterly earnings results on Tuesday, March 26th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.01). On average, research analysts expect that Vigil Neuroscience will post -2.09 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on VIGL. JMP Securities reaffirmed a "market outperform" rating and set a $23.00 target price on shares of Vigil Neuroscience in a research note on Thursday, April 18th. Wedbush reiterated an "outperform" rating and issued a $22.00 price objective on shares of Vigil Neuroscience in a research note on Wednesday. Finally, HC Wainwright reissued a "buy" rating and set a $24.00 target price on shares of Vigil Neuroscience in a research note on Wednesday.

Hedge Funds Weigh In On Vigil Neuroscience

Hedge funds have recently bought and sold shares of the business. Strs Ohio bought a new position in Vigil Neuroscience in the fourth quarter valued at about $27,000. PEAK6 Investments LLC increased its holdings in Vigil Neuroscience by 66.0% in the third quarter. PEAK6 Investments LLC now owns 23,796 shares of the company's stock valued at $128,000 after purchasing an additional 9,459 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Vigil Neuroscience by 11.9% in the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company's stock valued at $3,050,000 after buying an additional 95,276 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.